# Ribometrix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ribometrix

- Industry: Pharmaceuticals
- Headquarters: Durham, US
- Website: www.ribometrix.com
- Total disclosed funding: $38M
- Latest round: Series A (Nov 13, 2018)
- Investors on record: 10

## About

Ribometrix, Inc. specializes in innovative drug development, focusing on small molecule therapeutics that target and modulate cellular RNAs, aiming to correct the production of disease-causing proteins in various therapeutic areas.Founded in 2014 and headquartered in Durham, US, Ribometrix, Inc. develops small molecule drugs that modulate cellular RNAs. The company has raised a total of USD 7.80 mn, with the most recent funding of USD 7.80 mn occurring on August 1, 2022. Key investors include Dementia Discovery Fund and Illuminate Ventures. Ribometrix was co-founded by Katie Warner and Kevin Weeks, with Mike Solomon serving as CEO.Ribometrix focuses on developing innovative small molecule drugs that target and modulate cellular RNAs, which play a crucial role in the production of disease-causing proteins. Their primary offerings leverage a unique approach by correcting protein production through specific interactions with structural and functional "hot spots" in encoding mRNA. This can involve selective binding or the incorporation of engineered RNA-degrading components for situations where binding alone is insufficient. Ribometrix aims to address a variety of diseases across multiple therapeutic areas, appealing to a diverse client base that includes pharmaceutical companies and research institutions. The geographical markets served by Ribometrix extend beyond North Carolina, reaching international partners and clients in regions such as North America, Europe, and Asia, reflecting a broad interest in RNA-targeted therapeutics.Revenue generation for Ribometrix is structured through strategic partnerships and collaborations within the biopharmaceutical industry, focusing primarily on B2B transactions. These partnerships involve co-development agreements and research collaborations with pharmaceutical companies looking to leverage Ribometrix's RNA-targeting technology in their therapeutic pipelines. The financial arrangements typically include milestone payments and royalties tied to the successful development and commercialization of therapeutics derived from their proprietary platforms. While specific pricing plans or revenue figures for individual products/services have not been disclosed, Ribometrix's innovative approach positions them to attract significant investment and partnership opportunities, thereby fostering a sustainable revenue model based on their flagship RNA-targeting therapeutics.As of the most recent deal in Q3 2022, Ribometrix, Inc. is leveraging additional venture funding to enhance its drug development pipeline and is exploring opportunities for new product launches in RNA-targeted therapeutics. The company is looking to expand into international markets in Europe and Asia by the end of 2023, facilitated by the funds raised. This strategic focus indicates a commitment to increasing its global footprint and developing innovative solutions in the biopharmaceutical landscape.

## Funding rounds

- Series A, Nov 13, 2018, $30M — Pappas Capital, Alexandria Venture Investments, Hatteras Venture Partners, SV Health Investors, Amgen Ventures, M Ventures, MP Healthcare Venture Management, AbbVie Ventures, Illumina Ventures, Dementia Discovery Fund
- Seed, Oct 31, 2017, $7.5M — Alexandria Venture Investments, Hatteras Venture Partners, SV Health Investors, MP Healthcare Venture Management, AbbVie Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed, Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Seed, Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed, Series A
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Seed, Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Seed, Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A
- Dementia Discovery Fund — Series A